October 29, 2021 06:24 AM EDTUpdated November 8, 03:35 PM
Deals
R&D

Scoop: Eli Lil­ly and AC Im­mune qui­et­ly scrapped Alzheimer’s stud­ies for the cen­ter­piece of $2B deal months ago

Max Gelman

Senior Editor

In its quar­ter­ly earn­ings re­port Tues­day, Eli Lil­ly dis­closed it ceased de­vel­op­ment of an in-house, an­ti-tau Alzheimer’s pro­gram af­ter it missed the pri­ma­ry end­point in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

A service from the Financial Times